

1 **Running Title: NLP-RNAseq in AD**

2  
3  
4 **Association of RDoC dimensions with post-mortem brain transcriptional profiles**  
5 **in Alzheimer's Disease**

6  
7 Weiqian Jiang<sup>1,\*</sup>, Jonathan Vogelgsang<sup>1,\*</sup>, Shu Dan<sup>1</sup>, Peter Durning<sup>1</sup>, Thomas H. McCoy<sup>2</sup>,  
8 Sabina Berretta<sup>1,\*</sup>, and Torsten Klengel<sup>1,\*</sup>

9  
10 <sup>1</sup>Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA

11 <sup>2</sup>Center for Quantitative Health, Massachusetts General Hospital, Harvard Medical School, Boston, MA  
12 02114, USA

13 \* Denotes equal contribution

14  
15  
16  
17 Correspondence: Sabina Berretta MD, McLean Hospital, 115 Mill Street, Belmont MA 02478  
18 ([sberretta@mclean.harvard.edu](mailto:sberretta@mclean.harvard.edu)) and Torsten Klengel MD, PhD, McLean Hospital, 115 Mill Street,  
19 Belmont MA 02478 ([tklengel@mclean.harvard.edu](mailto:tklengel@mclean.harvard.edu))

20  
21  
22  
23  
24 **Acknowledgment statement:** This work was supported by P50MH115874, R01MH120991, German  
25 Research Foundation #413501650, P50NM119467, Alzheimer's Association #AACSF23-1149842, Eric  
26 Dorris Memorial Fellowship, Rappaport Mental Health Research Award, R01HD102974, and  
27 R01AG070704.

28  
29 **Author contributions:** WJ, JSV, TK and SB designed the study. WJ, JSV, SD, and PD performed analyses.  
30 WJ, JSV, TK and SB wrote the manuscript. All authors approved the final version of the manuscript.

31  
32 **Competing interests:** The authors have no conflict of interest to disclose.

33 **Abstract**

34

35 INTRODUCTION: Neuropsychiatric symptoms are common in people with Alzheimer’s disease (AD)  
36 across all severity stages. Their heterogeneous presentation and variable temporal association with  
37 cognitive decline suggest shared and distinct biological mechanisms. We hypothesized that specific  
38 patterns of gene expression associate with distinct NIMH Research Domain Criteria (RDoC) domains in  
39 AD.

40 METHODS: Post-mortem bulk RNAseq on the insula and anterior cingulate cortex from 60 brain donors  
41 representing the spectrum of canonical AD neuropathology combined with natural language processing  
42 approaches based on the RDoC Clinical Domains.

43 RESULTS: Distinct sets of >100 genes ( $p_{FDR}<0.05$ ) were specifically associated with at least one clinical  
44 domain (Cognitive, Social, Negative, Positive, Arousal). In addition, dysregulation of immune response  
45 pathways was shared across domains and brain regions.

46 DISCUSSION: Our findings provide evidence for distinct transcriptional profiles associated with RDoC  
47 domains suggesting that each dimension is characterized by specific sets of genes providing insight into  
48 the underlying mechanisms.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

## 65 Introduction

66  
67 Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia. While  
68 advanced stages of AD are characterized by severe cognitive impairment, varying degrees of  
69 neuropsychiatric symptoms (NPS) including depression, agitation, aggression, and apathy can be present  
70 across the entire spectrum of AD<sup>1,2</sup>. NPS can lead to accelerated disease progression, increased caregiver  
71 burden, and earlier death. Treatment of these symptoms with medications used for non-  
72 neurodegenerative psychiatric disorders is based on the largely unchallenged assumption that their  
73 biological underpinnings are equivalent. The clinical diagnosis of AD is based on a combination of clinical  
74 and pathological measurements, either biomarkers in cerebrospinal fluid (CSF) or PET imaging of  
75 Amyloid- $\beta$  or TAU deposition. Neuropathologically, AD is characterized by extracellular plaques of  
76 misfolded  $\beta$ -amyloid (A $\beta$ ) aggregates and intracellular neurofibrillary tangles (NFT) formed by paired  
77 helical filaments of hyperphosphorylated tau protein<sup>3</sup>. While deposition of A $\beta$  and NFT are considered  
78 neuropathological hallmarks of AD<sup>4</sup>, studies on transcriptional changes in AD using post-mortem brain  
79 tissue suggest the dysregulation of multiple cellular pathways including synaptic dysfunction, gliosis,  
80 demyelination, and inflammation leading to neuronal loss<sup>5-9</sup>. Bridging between canonical and molecular  
81 changes on one side and symptoms on the other is particularly challenging, even more so in the context  
82 of clinical, genetic, and neuropathological heterogeneity among persons with AD<sup>10</sup>.

83  
84 Most large-scale transcriptional studies focus on extensively studied brain regions such as hippocampus,  
85 anterior cingulate cortex (BA32/BA33) and prefrontal cortex (BA9, BA10, BA46)<sup>6-9,11,12</sup>. In contrast, the  
86 insula, which is located deep within the lateral sulcus that separates the temporal from the parietal and  
87 frontal lobes, remains largely understudied. It has been traditionally viewed as a paralimbic or limbic  
88 integration cortex integrating visceral information<sup>13,14</sup>. Recently, imaging studies have sparked  
89 considerable interest in investigating the role of the insular cortex in the context of emotion, pain,  
90 decision making, motor control, and social functions<sup>15</sup>. The insular cortex is connected to a wide variety  
91 of brain regions including the frontal, anterior cingulate and parietal cortex, limbic areas such as the  
92 amygdala, hypothalamus, and entorhinal cortex, and to sensorimotor brain regions<sup>16,17</sup>. The central role  
93 of the insular cortex in relevant circuits is supported by several neuroimaging studies suggesting its  
94 involvement in AD and AD-related NPS<sup>18-21</sup>. However, transcriptomic studies investigating molecular  
95 mechanisms underlying pathological alterations of the insular cortex in AD remain scarce.

96

97 To date, most transcriptomic studies focus on the comparison between normative individuals and people  
98 with either early- or late-onset AD<sup>5,8,12</sup>. Single-nucleus RNAseq studies have provided significant insight  
99 into AD pathology by revealing distinct gene expression patterns in multiple cell types<sup>22,23</sup>. Although very  
100 informative, categorical diagnosis comparison designs may not be well suited to account for  
101 interindividual heterogeneity in symptom presentation, particularly regarding comorbid NPS. To  
102 overcome these limitations, we previously applied a natural language processing (NLP) algorithm to post-  
103 mortem medical records of donors with and without AD to provide dimensional phenotyping within the  
104 context of the NIMH Research Domain Criteria (RDoC)<sup>24</sup>. RDoC is a multidimensional framework  
105 composed of different neuropsychiatric domains capturing a spectrum of symptoms rooted in brain  
106 circuits and biology<sup>25-27</sup>.

107  
108 In this study, we performed an RNAseq analysis in the anterior Insula (aINS; BA16) and dorsal anterior  
109 cingulate cortex (dACG; BA32), focusing on a dimensional approach based on the NIMH RDoC domain  
110 matrix including Negative Valence Systems, Positive Valence Systems, Cognitive Systems, Social  
111 Processes, and Arousal and Regulatory Systems. Using a generalized linear regression model, we show  
112 that transcriptomic changes associated with dimensional RDoC clinical domain scores provide a deeper  
113 and more nuanced insight into the underlying molecular correlates of dimensional symptoms  
114 presentation in AD. Importantly, our results suggest common and distinct molecular mechanisms across  
115 RDoC domains and brain regions.

116

## 117 **Methods**

118

### 119 ***Experimental Subjects and Tissue Preparation***

120 All tissue samples and medical records were obtained from the Harvard Brain Tissue Resource Center  
121 (HBTRC; operating under the MGB McLean Institutional Review Board (IRB)). The subject cohort (n=60)  
122 available for this study included brain donors representing the full spectrum of Braak & Braak  
123 neuropathological stages, thus representing the neuropathological AD progression from Braak and Braak  
124 stages 0 to II (unaffected controls) to Braak and Braak stages III and IV (mild to moderate AD pathology)  
125 and Braak and Braak stages V and VI (severe AD pathology)<sup>28</sup>. Only donors with sufficient medical  
126 records and a life diagnosis by a qualified clinician were included. Donors with significant psychiatric

127 conditions diagnosed during adolescence, early- or mid-adulthood were not included. Similarly, we  
128 excluded donors with non-AD neurological diagnoses.

129 Medical records in hard copies were scanned into computer-readable text files using optical character  
130 recognition. Text files were processed using RDoC-based NLP algorithms to obtain quantitative  
131 measures of clinical domain scores, as described by McCoy et al<sup>24</sup> ([https://github.com/thmccoy/CQH-](https://github.com/thmccoy/CQH-Dimensional-Phenotyper)  
132 [Dimensional-Phenotyper](https://github.com/thmccoy/CQH-Dimensional-Phenotyper)). Access to donors' medical records and other sensitive data was restricted to  
133 IRB-authorized investigators; all other investigators contributing to this study were given access to de-  
134 identified data, according to the Health Insurance Portability and Accountability Act (HIPAA) regulations.  
135 Detailed metadata information for each sample is given in **Supplementary Data 1**. A summary of the  
136 cohort subject basic data by RNA-seq batch is included in **Supplementary Data 2** and individual scores in  
137 each domain is given in **Supplementary Data 3**.

138 The dACG (BA32) and the aINS (BA16) were isolated from flash-frozen human post-mortem brain tissue  
139 samples. Tissue blocks were sectioned using a cryostat and 5 x 40µm sections (approximately 20 mg)  
140 were collected for RNA extraction using Absolutely RNA Miniprep Kit (Agilent, Lexington, MA) according  
141 to the manufacturer's protocol. Briefly, 400µl lysis buffer, including 2.8µl β-mercaptoethanol were  
142 added to the tissue and homogenized. 400µl 70% ethanol was added to the tissue homogenate and  
143 vortexed for 5 seconds. 400µl homogenate was transferred to an RNA Binding Spin Cup and centrifuges  
144 for 60 seconds at 16,000 x g and repeated once. The column was washed once with 600µl Low-Salt  
145 Wash Buffer and centrifuged at max speed to dry, followed by a 15-minute DNase I digestion at room  
146 temperature. Next, the column was washed with 600µl High-Salt Wash Buffer, 600µl Low-Salt Wash  
147 Buffer, and 300µl Low-Salt Wash Buffer, each step followed by 60 seconds centrifugation at max. speed.  
148 Lastly, 40µl Elution Buffer was added on the matrix and incubated for 120 seconds followed by  
149 centrifugation at maximum speed for 60 seconds.

### 150 ***RNA-Seq library preparation and sequencing***

151 RNA library preparation and sequencing were conducted at Azenta Life Sciences (South Plainfield, NJ,  
152 USA). Briefly, RNA samples were quantified using Qubit 2.0 Fluorometer (ThermoFisher Scientific,  
153 Waltham, MA, USA) and RNA integrity was checked with 4200 TapeStation (Agilent Technologies, Palo  
154 Alto, CA, USA). RNA samples were treated with TURBO DNase (Thermo Fisher Scientific, Waltham, MA,  
155 USA) to remove DNA following manufacturer's protocol. rRNA depletion sequencing libraries were

156 prepared by using QIAGEN Fastselect HMR. RNA sequencing library preparation uses NEBNext Ultra II  
157 RNA Library Preparation Kit for Illumina by following the manufacturer's recommendations (NEB,  
158 Ipswich, MA, USA). Briefly, enriched RNAs were fragmented for 15 minutes at 94 °C. First strand and  
159 second strand cDNA were subsequently synthesized. cDNA fragments were end repaired and adenylated  
160 at 3'ends, and universal adapters are ligated to cDNA fragments, followed by index addition and library  
161 enrichment with limited cycle PCR. Sequencing libraries were validated using the Agilent Tapestation  
162 4200 (Agilent Technologies, Palo Alto, CA, USA), and quantified using Qubit 2.0 Fluorometer  
163 (ThermoFisher Scientific, Waltham, MA, USA) as well as by quantitative PCR (KAPA Biosystems,  
164 Wilmington, MA, USA). Sequencing libraries were multiplexed and clustered onto a flow-cell. After  
165 clustering, the flow-cell was loaded onto the Illumina Novaseq instrument according to manufacturer's  
166 instructions. The samples were sequenced using a 2x150bp Paired End (PE) configuration. Image analysis  
167 and base calling were conducted by the Control Software. Raw sequence data (.bcl files) generated from  
168 Illumina was converted into fastq files and de-multiplexed using Illumina bcl2fastq 2.20 software. One  
169 mismatch was allowed for index sequence identification.

170

#### 171 ***Processing of RNA-seq data***

172 RNA-seq data was processed and analyzed using the bcbio-nextgen Bulk RNA-seq pipeline (available at  
173 <https://github.com/bcbio/bcbio-nextgen>). Paired-end sequence reads were aligned to human genome  
174 UCSC GRCh38.p14 using STAR<sup>29</sup>. Quality metrics were assessed using Samtools<sup>30</sup>, with an average  
175 mapping rate of 84%. No samples were excluded based on sequencing QC metrics. Transcript counts  
176 from aligned reads were quantified using Salmon<sup>31</sup>, then summarized to the gene level using the R  
177 package Tximport<sup>32</sup>. Sequencing depth was normalized between samples using the median of ratios  
178 method in R package DESeq2<sup>33</sup>. Low expressed genes with less than 10 reads in over half of the total  
179 sample were removed.

#### 180 ***Differential Expression Analysis over Clinical Domain Scores***

181 Scores for RDoC-based clinical domains were derived using NLP algorithms as previously described in  
182 Vogelgsang et al.<sup>34</sup> The clinical domain scores of all donors were binned between 0 and 1, in 0.1 intervals  
183 and considered on a dimensional scale from 0 (lower limit) to 1 (upper limit) (**Supplementary Data 3**).  
184 Note that higher scores indicate more severe symptoms (e.g. more severe cognitive impairment); thus, a  
185 positive correlation between gene expression and clinical domain scores indicates that higher gene

186 expression is associated with greater symptom severity. Differential gene expression analyses in the aINS  
187 and dACG for over dimensional scores for each of the 5 clinical domains using the filtered gene set was  
188 performed by ImpulseDE2<sup>35</sup>.

189  
190 Briefly, after filtering, normalized counts were used in a principal component analysis (PCA) to identify  
191 potential covariates. The first five PCs were correlated with known technical and biological variables,  
192 resulting in significant correlations for neuropathological Braak & Braak stage, brain region, sex, age, RIN,  
193 and sequencing batch, but not PMI (**Supplementary Figure 1**). To further explore residual unknown  
194 sources of variation including the influence of changing cell type composition, medication, and  
195 comorbidities, surrogate variable analysis (SVA)<sup>36</sup> was used, which yielded two significant SVs correlated  
196 with the first five PCs. Given the overall influence of Braak & Braak stages, brain regions, sex, age, RIN,  
197 sequencing batch, SV1, and SV2 on the data, we further explored the relevance of covariates across the  
198 RDoC cognition domain for each brain region and found that sex, sequencing batch and Braak & Braak  
199 status showed significant associations, while age, RIN, PMI, SV1, and SV2 were not significantly  
200 associated across the dimension (**Supplementary Data 1**). Thus, the final model to identify genes  
201 progressively regulated along the axis from low to high clinical domain scores in ImpulseDE2 included sex  
202 and sequencing batch as covariates. Braak and Braak stage was not included due to collinearity with the  
203 clinical domain scores. Statistical significance of differential expression was defined at  $p_{FDR} < 0.05$ .

204

### 205 ***Functional Enrichment Analysis***

206 A one-tailed hypergeometric test was conducted for pathway enrichment analysis using Metascape<sup>37</sup>.  
207 We included multiple databases such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and  
208 Genomes (KEGG), Reactome and Wikipathway, separately for up- and downregulated differentially  
209 expressed (DE) genes from the dimensional analyses. Statistical significance was defined at  $p_{FDR} < 0.05$ .

210

### 211 ***Data Availability***

212 RNAseq data is available through the GEO accession number GSE261050. The code of the analyses is  
213 available at the Klengel Lab GitHub page under [https://github.com/klengellab/RDoC\\_RNAseq](https://github.com/klengellab/RDoC_RNAseq).

214

215

216

217 **Results**

218

219 ***Differential Gene Expression in aINS and dACG as a Function of Dimensional Cognition Scores***

220

221 In a previous proof-of-concept work, we used NLP algorithms to obtain cognition scores and showed that  
222 they are significantly associated with neuritic plaque load across all lobes of the brain<sup>38</sup>. The correlation  
223 of this classical neuropathological hallmark of AD with compelling evidence for a direct relationship to  
224 cognition<sup>28,39,40</sup> and cognition scores provided evidence for the feasibility and validity of post-mortem  
225 dimensional phenotyping of brain donor electronic health records beyond categorical diagnoses,  
226 allowing for a more granular investigation of neuropsychiatric symptoms in AD.

227

228 Because the donor cohort available for this study only partially overlaps with the prior one<sup>38</sup>, we again  
229 tested the association between neuritic plaque load and cognitive symptom burden. As expected, the  
230 cohort analyzed here showed a significant association between neuritic plaque load across all lobes and  
231 cognition scores, as well as a significant association of Braak & Braak stages with cognition scores  
232 **(Supplementary Data 4)**.

233

234 To investigate the underlying molecular changes associated with dimensional cognition burden, we  
235 regressed cognition scores over gene expression in the dACG and aINS of all donors, representing the full  
236 spectrum of Braak & Braak stages (from 0 to VI) using ImpulseDE2<sup>35</sup>. In the aINS, 109 DEGs at  $p_{FDR}<0.05$   
237 showed a monotonous increase or decrease of expression across cognition score **(Figure 1 A,**  
238 **Supplementary Data 5)**. Out of these 109 genes, 67 genes were positively correlated with more severe  
239 cognitive impairment. Top hits included genes involved in innate immune response, such as *CD177* and  
240 *HSPA6*. The remaining 42 genes were negatively correlated with cognition scores. These included  
241 *PNMA6B*, a member of paraneoplastic Ma antigen (PNMA) family, which is associated with immune-  
242 related diseases and neurological disorders<sup>41,42</sup>, alongside a large number of non-coding RNAs (ncRNAs)  
243 and pseudogenes.

244

245 In dACG, 107 DEGs ( $p_{FDR}<0.05$ ) showed a monotonous increased or decreased expression in association  
246 with cognition scores **(Figure 1 B, Supplementary Data 5)**. Among the 48 genes with increased  
247 expression associated with more severe cognition scores, *LAD1* and *MMP23A* were the top hits, with a  
248 strong positive correlation with cognitive impairment. Similar to the aINS, top downregulated DEGs



249 primarily belong to the less known group of pseudogenes or ncRNAs, with a total of 59 genes showing  
250 significant negative correlation with cognition severity.

### 251 ***Differential Gene Expression in aINS and dACG as a Function of Clinical Domain Scores***

252 Next, we focused on the Arousal Regulatory, Negative Valence, Positive Valence, and Social Systems  
253 domain scores. As expected, all domains were highly intercorrelated (Pearson  $r=0.88 \pm 0.04$ ). As shown  
254 in **Figure 2 A** and **Supplementary Data 5**, each clinical domain was associated with distinct sets of DEGs  
255 (all  $p_{FDR}<0.05$ ). In the aINS, DEGs were detected in association with Arousal (56 genes increased; 45  
256 genes decreased), Negative valence (40 genes increased; 56 decreased), Positive valence (61 genes  
257 increased; 61 genes decreased) and Social domain (61 genes increased; 49 genes decreased). Similar  
258 number of DEGs were detected in dACG in association with Arousal (42 genes increased; 52 genes  
259 decreased), Negative valence (65 genes increased; 60 genes decreased), Positive valence (46 increased;  
260 55 genes decreased) and Social domain (55 genes increased and 65 genes decreased (**Figure 2 B and**  
261 **Supplementary Data 5**). Notably, the majority of DEGs in aINS and dACG were uniquely associated with  
262 one domain with moderate to minimal overlap between domains (**Figure 2 C and D Supplementary Data**  
263 **5 and 6**).

### 264 ***Pathway Enrichment in aINS and dACG as a Function of Clinical Domain Scores***

265 Next, we assessed functional pathways across all clinical domains in aINS and dACG. Across both brain  
266 regions and all clinical domains, we found a predominating enrichment of pathways related to immune  
267 system functions. Enrichment analyses in the aINS revealed multiple pathways associated with innate  
268 immune responses shared across the five domains (**Figure 2 E, Supplementary Data 7**), including  
269 neutrophil degranulation, LPS response and leukocyte migration, supporting the notion that immune  
270 dysregulation is a driving factor for AD disease progression across all clinical domains investigated. In  
271 contrast to the broad association of innate immune response pathways with all clinical domains, other  
272 functional pathways were unique to a specific domain or a subset of domains. Specifically, pathways  
273 associated with the cognition domain included those involved in learning and memory, microtubule-  
274 based movement, circadian rhythm, and response to TGF- $\beta$ . Moreover, pathways related to sex  
275 hormones were unique to the arousal, cognition, and negative domain. As an example, FSHB, beta  
276 subunit of follicle-stimulating hormone was specifically increased in domain arousal and cognition. This  
277 hormone, crucial in the female reproductive cycle as well as in stimulating production and maturation of

278 sperm in males, has been shown to accelerate amyloid- $\beta$  and Tau deposition in neurons and to impair  
279 cognition in an AD rodent model<sup>43</sup>, and sex steroid hormones have been associated with AD onset as  
280 well as progression<sup>44</sup>. Very similar shared biological processes were detected among the five domains in  
281 BA32 (**Figure 2 F, Supplementary Data 7**). Unique pathways included complement activation shared by  
282 domain arousal, cognition and social, which has been associated with A $\beta$  clearance<sup>45</sup>.

283

## 284 Discussion

285

286 Historically, investigations on AD placed emphasis on the pathogenesis of canonical findings such as  
287 neurofibrillary tangles and senile plaques. Although the relevance of  $\beta$ -amyloid and tau proteinopathies  
288 is uncontroversial, growing evidence supports the contribution of additional molecular pathways such as  
289 immune regulation, oxidative stress, insulin signaling and lipid metabolism, synaptic regulation and sex  
290 hormone signaling<sup>46,47</sup>.

291

292 The relationship between AD neuropathology and dysregulation of molecular pathways on the one hand  
293 and AD symptomatology on the other hand has been predominantly investigated in the context of  
294 categorical diagnosis frameworks and with strong emphasis on cognitive impairment. However,  
295 categorical diagnoses have been criticized for their limitations and their potential to impede scientific  
296 progress<sup>48</sup>. Over the last decade, efforts have been made to overcome these limitations by establishing  
297 dimensional models of human cognition, behavior and emotions that are based on neurobiological or  
298 behavioral phenotypes such as RDoC or HiTOP<sup>49,50</sup>. Although these efforts are not without controversy,  
299 dimensional phenotyping across diagnostic entities is a promising approach to identify molecular  
300 mechanisms behind distinct symptoms and syndromes. Distinct neuropathological and molecular  
301 patterns may, at least in part, account for the heterogenous clinical presentation of neuropsychiatric  
302 disorders including AD<sup>51</sup>.

303

304 We previously investigated the relationship between continuous cognitive symptom dimension in AD  
305 and classical neuropathological changes. Our results confirmed an association of NLP-derived cognitive  
306 scores with hallmark neuropathological findings and provided a proof-of-concept supporting the validity  
307 of NLP-based methodologies to obtain quantitative measures of functional RDoC domains from post-  
308 mortem health records. Here we link dimensional clinical domain scores to bulk RNAseq data on 101

309 post-mortem brain samples from aINS and dACG to test the hypothesis that gene expression signatures  
310 are associated with dimensional phenotype constructs derived from post-mortem brain donor health  
311 records. Our results provide evidence for gene expression signatures that define each clinical domain  
312 and brain region, potentially facilitating future research into more granular phenotypes beyond  
313 categorical diagnoses. Our data also suggest immune-related transcriptional changes as a common  
314 underlying mechanism across all domains and brain regions.

315  
316 Results of linear regression models across all clinical domains in both brain regions yielded between  
317 n=94 and n=125 DEGs associated with one of the domains (**Supplemental Data 5**). Comparisons of up-  
318 or downregulated DEGs showed only a moderate level of overlap between clinical domains, suggesting  
319 that each domain may be defined by a specific set of differentially expressed genes (**Figure 2 C and D**).  
320 Notably, immune response pathways were robustly dysregulated across all clinical domains. These  
321 findings contribute to growing evidence for a critical role of immune signaling factors in AD and suggest  
322 their pervasive contribution to the overall clinical presentation of this disorder.

323  
324 We detected a substantial number of FDR-significant DEGs with an increasing or decreasing expression  
325 pattern over cognition scores in aINS (n=109 DEGs) and dACG (n=107 DEGs) (**Figure 1 A and B**). In the  
326 aINS, a subset of genes was uniquely differentially expressed in association with the cognitive domain  
327 (upregulated n=26, downregulated n=16, **Figure 2 C, Supplementary Data 7**) including *H2AC7* and *LCN2*  
328 (both upregulated). *H2AC7*, a H2A histone protein variant, is involved in regulating cell cycle processes.  
329 Interestingly, reactivation of cell cycle related genes and DNA double-strand breaks are early pathological  
330 hallmarks of AD, and eventually lead to neuronal loss<sup>52,53</sup>. *LCN2* is involved in a wide range of biological  
331 processes such as regulation of iron homeostasis, inflammation, cell death, survival, differentiation and  
332 migration<sup>54</sup>. *LCN2* in the brain has been implicated in cognition and behavior while increased levels of  
333 *LCN2* are associated with age-related CNS diseases such as AD and PD<sup>55</sup>. In the dACG, a total of 38 genes  
334 were uniquely differentially expressed with the cognitive domain (upregulated n=19, downregulated  
335 n=19, **Figure 2 D, Supplementary Data 7**). Top hits include *LAD1* and *MMP23A* which showed a strong  
336 positive correlation with cognition scores. *LAD1* is involved in cell anchoring and adhesion and *MMP23A*  
337 is one of the matrix metalloproteinase (MMP) family engaged in cell adhesion and matrix degradation in  
338 the extracellular matrix (ECM), enhancing immune cells migration and inflammatory response<sup>56</sup>.

339

340 DEGs that are uniquely up- or down-regulated over specific clinical domains may shed light on  
341 underlying molecular mechanisms of NPS in AD. For example, *PINX1* and *HSPA7* showed a unique  
342 signature of increased expression over the arousal domain in the aINS. *PINX1* can inhibit the activity of  
343 telomerase, which is protective against ROS production and oxidative stress at different stages of AD  
344 pathology<sup>57</sup>. Interestingly, telomerase activity is also associated with circadian oscillation under the  
345 control of CLOCK-BMAL1 heterodimers<sup>58</sup>, a molecular mechanism fundamental to the arousal domain.  
346 *HSPA7* is a member of the human Hsp70 family and overexpression of Hsp70 can have protective effects  
347 on neurons in AD<sup>59</sup>. *AMIGO3* is among genes uniquely associated with the positive domain in the aINS.  
348 *AMIGO3* triggers the inhibition of oligodendrocyte precursor cell maturation, myelin production and  
349 neurite outgrowth<sup>60</sup>. Similar, we found *NPAS4* showing a unique positive association with the positive  
350 domain in the aINS. *NPAS4* encodes a transcription factor that regulates a number of downstream genes  
351 such as *BDNF*, *NARP* and *KCNA1*, which mediate diverse effects of synaptic modulation and experience-  
352 dependent memory formation<sup>61</sup>. Two other genes uniquely upregulated in association with the social  
353 domain in the aINS are *NME8* and *E2F8*. *NME8*, encoding TXNDC3 is involved in cytoskeletal function and  
354 axonal transport and identified as late-onset AD risk gene from GWAS and meta-analysis<sup>62</sup>. *E2F8* is a  
355 member of E2F transcription factor family that regulate the transition from G1 to S phase, and aberrant  
356 activation of neuronal cell cycle has also been postulated as a mechanism of neuronal loss in AD<sup>63</sup>. Lastly,  
357 IL6, a major inflammatory marker, showed an increasing expression pattern in association with the  
358 negative domain in the aINS. This is consistent with previous meta-analyses showing positive association  
359 between inflammatory markers and depression<sup>64</sup>.

360  
361 Several FDR-significant up- and downregulated genes were uniquely associated with individual clinical  
362 domains in the dACG. For example, *CNTF*, encoding a neurotrophic factor involved in neurotransmitter  
363 synthesis and neurite outgrowth, was uniquely upregulated in the social domain. *PINX1* was upregulated  
364 across the positive domain but downregulated across the cognitive and negative domain in the dACG.  
365 Interestingly it shows a unique upregulation with arousal in BA16 (*see above*). *SLC5A1*, encoding the  
366 sodium/glucose cotransporter SGLT1 and *LCN2*, encoding a glycoprotein expressed in reactive microglia  
367 and astrocytes in AD, were uniquely associated with the positive domain our cohort<sup>65</sup>. Genes associated  
368 with the negative domain and prior evidence for a role in AD included *IL1RL1*, *LIF*, and *FGB*<sup>66-68</sup>.

369  
370 Although the number of overlapping DEGs across clinical domains was small (**Figure 2 C and D**), these  
371 genes could point to molecular mechanisms that influence a broader set of symptoms in AD. Common

372 upregulated genes across all domains (including the cognitive domain) in the aINS indicate the overall  
373 activation of processes related to immune activation, which is an important mechanism contributing to  
374 AD pathogenesis and progression. For example, we found *CXCL10*, a chemokine that can mediate  
375 immune activation by binding to its receptor *CXCR3* and activate and recruit leukocytes<sup>69</sup>. We also found  
376 *MUC13*, which promotes NF- $\kappa$ B activity and leads to increased production of IL-8<sup>70</sup>. On the other hand,  
377 as a subtype of mucins, mature MUC13 can provide numerous glycosylation sites with its N-terminus  
378 located on the cell surface, and N-linked glycosylation has been recently reported to affect the  
379 progression of AD<sup>71</sup>. In total, we detect n=70 genes upregulated at  $p_{\text{FDR}} < 0.05$  across at least two domains.  
380 In contrast, n=70 downregulated genes at  $p_{\text{FDR}} < 0.05$  are shared across at least two domains  
381 **(Supplementary Data 6)**.

382  
383 In the dACG, several genes including *USP17L11*, *USP17L17*, *USP17L26*, and *USP17L28* were upregulated  
384 across different clinical domains. They belong to the deubiquitinating enzyme (DUB) family of genes and  
385 are involved in regulating the removal of ubiquitin molecules from proteins<sup>72</sup>. The ubiquitin-proteasome  
386 system (UPS) maintains mitochondrial homeostasis by regulating mitochondrial proteome and  
387 mitophagy<sup>73</sup>. UPS impairment and mitochondrial dysfunction have been implicated as hallmarks of aging  
388 and associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson disease<sup>74,75</sup>.  
389 Notably, *MT-RNR2*, encoding the polypeptide Humanin, is also upregulated across the cognitive, arousal,  
390 and social domain in the dACG<sup>76</sup>. In total, we detect n=66 genes upregulated at  $p_{\text{FDR}} < 0.05$  across at least  
391 two domains. In contrast, n=78 downregulated genes at  $p_{\text{FDR}} < 0.05$  are shared across at least two  
392 domains **(Supplementary Data 6)**.

393 At the level of regulatory pathways, we found a more congruent profile with shared pathways related to  
394 the innate immune response defining upregulated gene profiles, and GTPase activity defining  
395 downregulated gene profiles across domains and **(Figure 2 E and F, Supplemental Data 7)**. This  
396 contrasting result compared to the regulation of individual genes may reflect the overall strong impact of  
397 immune dysregulation, vesicle trafficking, and cell cycle regulation in AD progression.

398  
399 In summary, the use of NLP-derived dimensional phenotypes may provide more specific insight into the  
400 underlying biology of AD. Each clinical domain score was associated with a distinct pattern of DEGs with  
401 a limited number of DEGs shared across domains. However, changes across clinical domains may be  
402 driven by shared functional pathways with a focus on immune system dysregulation.

403 **References**

404

- 405 1 Sabates, J. *et al.* The Associations Between Neuropsychiatric Symptoms and Cognition in People  
406 with Dementia: A Systematic Review and Meta-Analysis. *Neuropsychology Review* **34**, 581-597,  
407 doi:10.1007/s11065-023-09608-0 (2024).
- 408 2 Zhao, Q. F. *et al.* The prevalence of neuropsychiatric symptoms in Alzheimer's disease:  
409 Systematic review and meta-analysis. *J Affect Disord* **190**, 264-271,  
410 doi:10.1016/j.jad.2015.09.069 (2016).
- 411 3 Braak, H., Ra, d. V., En, J. S., Bratzke, H. & Braak, E. v. J. P. i. b. r. Neuropathological hallmarks of  
412 Alzheimer's and Parkinson's diseases. **117**, 267-285 (1998).
- 413 4 Strooper, B. D. & Karran, E. J. C. The Cellular Phase of Alzheimer's Disease. **164**, 603-615 (2016).
- 414 5 Colangelo, V. *et al.* Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1:  
415 transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-  
416 inflammatory signaling. **70**, 462-473 (2002).
- 417 6 Zhang, B. *et al.* Integrated systems approach identifies genetic nodes and networks in late-onset  
418 Alzheimer's disease. **153**, 707-720 (2013).
- 419 7 Miller, J. A., Woltjer, R. L., Goodenbour, J. M., Horvath, S. & Geschwind, D. H. J. G. m. Genes and  
420 pathways underlying regional and cell type changes in Alzheimer's disease. **5**, 1-17 (2013).
- 421 8 Bossers, K. *et al.* Concerted changes in transcripts in the prefrontal cortex precede  
422 neuropathology in Alzheimer's disease. **133**, 3699-3723 (2010).
- 423 9 Neff, R. A. *et al.* Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals  
424 novel mechanisms and targets. **7** (2021).
- 425 10 Lam, B. *et al.* Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease  
426 syndrome. **5**, 1-14 (2013).
- 427 11 Annese, A. *et al.* Whole transcriptome profiling of Late-Onset Alzheimer's Disease patients  
428 provides insights into the molecular changes involved in the disease. **8**, 4282 (2018).
- 429 12 Van Rooij, J. G. *et al.* Hippocampal transcriptome profiling combined with protein-protein  
430 interaction analysis elucidates Alzheimer's disease pathways and genes. **74**, 225-233 (2019).
- 431 13 Augustine, J. R. J. B. r. r. Circuitry and functional aspects of the insular lobe in primates including  
432 humans. **22**, 229-244 (1996).
- 433 14 Showers, M. J. C. & Lauer, E. W. J. J. o. C. N. Somatovisceral motor patterns in the insula. **117**,  
434 107-115 (1961).
- 435 15 Kurth, F. *et al.* A link between the systems: functional differentiation and integration within the  
436 human insula revealed by meta-analysis. **214**, 519-534 (2010).
- 437 16 Molnar-Szakacs, I., Uddin, L. Q. J. N. & Reviews, B. Anterior insula as a gatekeeper of executive  
438 control. **139**, 104736 (2022).
- 439 17 Gogolla, N. J. C. B. The insular cortex. **27**, R580-R586 (2017).
- 440 18 Dai, Z. *et al.* Identifying and mapping connectivity patterns of brain network hubs in Alzheimer's  
441 disease. **25**, 3723-3742 (2015).
- 442 19 Fathy, Y. Y. *et al.* Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a  
443 systematic review and meta-analysis. **14**, 2799-2816 (2020).
- 444 20 Jones, S. A. *et al.* Altered frontal and insular functional connectivity as pivotal mechanisms for  
445 apathy in Alzheimer's disease. **119**, 100-110 (2019).
- 446 21 Liu, X. *et al.* Altered functional connectivity of insular subregions in Alzheimer's disease. **10**, 107  
447 (2018).
- 448 22 Gazestani, V. *et al.* Early Alzheimer's disease pathology in human cortex involves transient cell  
449 states. **186**, 4438-4453. e4423 (2023).



- 450 23 Mathys, H. *et al.* Single-cell atlas reveals correlates of high cognitive function, dementia, and  
451 resilience to Alzheimer's disease pathology. **186**, 4365-4385. e4327 (2023).
- 452 24 McCoy Jr, T. H. *et al.* High throughput phenotyping for dimensional psychopathology in electronic  
453 health records. **83**, 997-1004 (2018).
- 454 25 Insel, T. *et al.* Vol. 167 748-751 (Am Psychiatric Assoc, 2010).
- 455 26 Cuthbert, B. N. J. W. p. The RDoC framework: facilitating transition from ICD/DSM to dimensional  
456 approaches that integrate neuroscience and psychopathology. **13**, 28-35 (2014).
- 457 27 Carcone, D. & Ruocco, A. C. J. F. i. c. n. Six years of research on the national institute of mental  
458 health's research domain criteria (RDoC) initiative: a systematic review. **11**, 46 (2017).
- 459 28 Braak, H. & Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol*  
460 *Aging* **16**, 271-278; discussion 278-284, doi:10.1016/0197-4580(95)00021-6 (1995).
- 461 29 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21,  
462 doi:10.1093/bioinformatics/bts635 (2013).
- 463 30 Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *GigaScience* **10**, giab008,  
464 doi:10.1093/gigascience/giab008 (2021).
- 465 31 Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-  
466 aware quantification of transcript expression. *Nature Methods* **14**, 417-419,  
467 doi:10.1038/nmeth.4197 (2017).
- 468 32 Sonesson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level  
469 estimates improve gene-level inferences. *F1000Res* **4**, 1521, doi:10.12688/f1000research.7563.2  
470 (2015).
- 471 33 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-  
472 seq data with DESeq2. *Genome Biology* **15**, 550, doi:10.1186/s13059-014-0550-8 (2014).
- 473 34 Vogelgsang, J. S. *et al.* Dimensional clinical phenotyping using post-mortem brain donor medical  
474 records: Association with neuropathology. 2023.2005. 2004.539430 (2023).
- 475 35 Fischer, D. S., Theis, F. J. & Yosef, N. Impulse model-based differential expression analysis of time  
476 course sequencing data. *Nucleic Acids Research* **46**, e119-e119, doi:10.1093/nar/gky675 (2018).
- 477 36 Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing  
478 batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**,  
479 882-883, doi:10.1093/bioinformatics/bts034 (2012).
- 480 37 Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level  
481 datasets. *Nature Communications* **10**, 1523, doi:10.1038/s41467-019-09234-6 (2019).
- 482 38 Vogelgsang, J. *et al.* Dimensional clinical phenotyping using post-mortem brain donor medical  
483 records: post-mortem RDoC profiling is associated with Alzheimer's disease neuropathology.  
484 *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **15**, e12464,  
485 doi:<https://doi.org/10.1002/dad2.12464> (2023).
- 486 39 Mufson, E. J. *et al.* Braak stage and trajectory of cognitive decline in noncognitively impaired  
487 elders. *Neurobiology of Aging* **43**, 101-110,  
488 doi:<https://doi.org/10.1016/j.neurobiolaging.2016.03.003> (2016).
- 489 40 Nelson, P. T., Braak, H. & Markesbery, W. R. Neuropathology and cognitive impairment in  
490 Alzheimer disease: a complex but coherent relationship. *J Neuropathol Exp Neurol* **68**, 1-14,  
491 doi:10.1097/NEN.0b013e3181919a48 (2009).
- 492 41 Schüller, M., Jenne, D. E. & Voltz, R. J. J. o. N. The human PNMA family: Novel neuronal proteins  
493 implicated in paraneoplastic neurological disease. **169**, 172-176 (2005).
- 494 42 Pang, S. W., Lahiri, C., Poh, C. L. & Tan, K. O. J. C. s. PNMA family: Protein interaction network and  
495 cell signalling pathways implicated in cancer and apoptosis. **45**, 54-62 (2018).
- 496 43 Xiong, J. *et al.* FSH blockade improves cognition in mice with Alzheimer's disease. *Nature* **603**,  
497 470-476, doi:10.1038/s41586-022-04463-0 (2022).

- 498 44 Fisher, D. W., Bennett, D. A. & Dong, H. J. N. o. a. Sexual dimorphism in predisposition to  
499 Alzheimer's disease. **70**, 308-324 (2018).
- 500 45 Heneka, M. T. *et al.* Neuroinflammation in Alzheimer's disease. **14**, 388-405 (2015).
- 501 46 Eteleeb, A. M. *et al.* Brain high-throughput multi-omics data reveal molecular heterogeneity in  
502 Alzheimer's disease. *PLoS Biol* **22**, e3002607, doi:10.1371/journal.pbio.3002607 (2024).
- 503 47 Saura, C. A., Deprada, A., Capilla-López, M. D. & Parra-Damas, A. Revealing cell vulnerability in  
504 Alzheimer's disease by single-cell transcriptomics. *Seminars in Cell & Developmental Biology* **139**,  
505 73-83, doi:<https://doi.org/10.1016/j.semcdb.2022.05.007> (2023).
- 506 48 Ross, C. A. & Margolis, R. L. Research Domain Criteria: Strengths, Weaknesses, and Potential  
507 Alternatives for Future Psychiatric Research. *Mol Neuropsychiatry* **5**, 218-236,  
508 doi:10.1159/000501797 (2019).
- 509 49 Dalgleish, T., Black, M., Johnston, D. & Bevan, A. Transdiagnostic approaches to mental health  
510 problems: Current status and future directions. *J Consult Clin Psychol* **88**, 179-195,  
511 doi:10.1037/ccp0000482 (2020).
- 512 50 Hengartner, M. P. & Lehmann, S. N. Why Psychiatric Research Must Abandon Traditional  
513 Diagnostic Classification and Adopt a Fully Dimensional Scope: Two Solutions to a Persistent  
514 Problem. *Front Psychiatry* **8**, 101, doi:10.3389/fpsyt.2017.00101 (2017).
- 515 51 Fisher, D. W. *et al.* Unique transcriptional signatures correlate with behavioral and psychological  
516 symptom domains in Alzheimer's disease. *Translational Psychiatry* **14**, 178, doi:10.1038/s41398-  
517 024-02878-z (2024).
- 518 52 Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J. & Tsai, L.-H. J. T. J. o. N. Amyloid-  
519 Independent Mechanisms in Alzheimer's Disease Pathogenesis. **30**, 14946 - 14954 (2010).
- 520 53 Dileep, V. *et al.* Neuronal DNA double-strand breaks lead to genome structural variations and 3D  
521 genome disruption in neurodegeneration. **186**, 4404-4421.e4420 (2023).
- 522 54 Ferreira, A. C. *et al.* From the periphery to the brain: Lipocalin-2, a friend or foe? **131**, 120-136  
523 (2015).
- 524 55 Dekens, D. W. *et al.* Lipocalin 2 as a link between ageing, risk factor conditions and age-related  
525 brain diseases. **70**, 101414 (2021).
- 526 56 Velasco, G. *et al.* Cloning and characterization of human MMP-23, a new matrix  
527 metalloproteinase predominantly expressed in reproductive tissues and lacking conserved  
528 domains in other family members. **274**, 4570-4576 (1999).
- 529 57 Wang, X. *et al.* Distinct roles of telomerase activity in age-related chronic diseases: An update  
530 literature review. **167**, 115553 (2023).
- 531 58 Chen, W.-D. *et al.* The circadian rhythm controls telomeres and telomerase activity. **451**, 408-414  
532 (2014).
- 533 59 Lyon, M. S. & Milligan, C. J. N. L. Extracellular heat shock proteins in neurodegenerative diseases:  
534 new perspectives. **711**, 134462 (2019).
- 535 60 Foale, S., Berry, M., Logan, A., Fulton, D. & Ahmed, Z. J. N. r. r. LINGO-1 and AMIGO3, potential  
536 therapeutic targets for neurological and dysmyelinating disorders? **12**, 1247 (2017).
- 537 61 Sun, X. & Lin, Y. J. T. i. n. Npas4: linking neuronal activity to memory. **39**, 264-275 (2016).
- 538 62 Lambert, J.-C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for  
539 Alzheimer's disease. **45**, 1452-1458 (2013).
- 540 63 Currais, A., Hortobágyi, T. & Soriano, S. J. A. The neuronal cell cycle as a mechanism of  
541 pathogenesis in Alzheimer's disease. **1**, 363 (2009).
- 542 64 Valkanova, V., Ebmeier, K. P. & Allan, C. L. J. J. o. a. d. CRP, IL-6 and depression: a systematic  
543 review and meta-analysis of longitudinal studies. **150**, 736-744 (2013).
- 544 65 Ishida, N. *et al.* SGLT1 participates in the development of vascular cognitive impairment in a  
545 mouse model of small vessel disease. **727**, 134929 (2020).



- 546 66 Jiang, Y. *et al.* An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4  
547 in female patients with Alzheimer's disease. **2**, 616-634 (2022).
- 548 67 Soilu-Hänninen, M. *et al.* Expression of LIF and LIF receptor beta in Alzheimer's and Parkinson's  
549 diseases. **121**, 44-50 (2010).
- 550 68 Bian, Z. *et al.* Accelerated accumulation of fibrinogen peptide chains with Aβ deposition in  
551 Alzheimer's disease (AD) mice and human AD brains. **1767**, 147569 (2021).
- 552 69 Michlmayr, D., McKimmie, C. S. J. I. j. o. i., cytokine & research, m. Role of CXCL10 in central  
553 nervous system inflammation. 1-18 (2014).
- 554 70 Sheng, Y. *et al.* MUC1 and MUC13 differentially regulate epithelial inflammation in response to  
555 inflammatory and infectious stimuli. **6**, 557-568 (2013).
- 556 71 Zhao, J. & Lang, M. J. C. D. D. New insight into protein glycosylation in the development of  
557 Alzheimer's disease. **9**, 314 (2023).
- 558 72 Komander, D., Clague, M. J. & Urbé, S. J. N. r. M. c. b. Breaking the chains: structure and function  
559 of the deubiquitinases. **10**, 550-563 (2009).
- 560 73 Ross, J. M., Olson, L. & Coppotelli, G. J. I. j. o. m. s. Mitochondrial and ubiquitin proteasome  
561 system dysfunction in ageing and disease: two sides of the same coin? **16**, 19458-19476 (2015).
- 562 74 Hanpude, P., Bhattacharya, S., Dey, A. K. & Maiti, T. K. J. I. I. Deubiquitinating enzymes in cellular  
563 signaling and disease regulation. **67**, 544-555 (2015).
- 564 75 Harrigan, J. A., Jacq, X., Martin, N. M. & Jackson, S. P. J. N. r. D. d. Deubiquitylating enzymes and  
565 drug discovery: emerging opportunities. **17**, 57-78 (2018).
- 566 76 Niikura, T. J. B. e. B. A.-G. S. Humanin and Alzheimer's disease: The beginning of a new field.  
567 **1866**, 130024 (2022).

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585 **Figure Legends**

586

587 **Figure 1. Transcriptional signature of dimensional RDoC cognition profiling.**

588 (A) Heatmap showing gene expression signatures of all DEGs ( $p_{\text{nominal}} < 0.05$ ) with a significant up- or  
589 down-regulated pattern over increasing RDoC cognition values in the dACG. The top ten up- or down-  
590 regulated DEGs (all  $p_{\text{FDR}} < 0.05$ ) are labeled. Bar colors on the left side indicate whether genes are  
591 clustered in an increasing (red) or decreasing (blue) trajectory. (B) Heatmap showing gene expression of  
592 DEGs ( $p_{\text{nominal}} < 0.05$ ) with a significant up- or down-regulated pattern over increasing RDoC cognition  
593 values in the aINS. Top ten up- or down-regulated monotonous DEGs (all  $p_{\text{FDR}} < 0.05$ ) are labeled.

594

595 **Figure 2. Identification of gene expression programs as a function of distinct RDoC cldomains**

596 (A) Heatmaps showing expression trajectories of up- or down-regulated DEGs ( $p_{\text{nominal}} < 0.05$ ) over  
597 increasing RDoC domain values separated for arousal, negative, positive and social in the dACG. Top ten  
598 up- or down-regulated DE genes (all  $p_{\text{FDR}} < 0.05$ ) labeled. (B) Heatmaps showing analogous expression  
599 pattern in the aINS, separated for arousal, negative, positive and social. (C) Upset plots showing the  
600 overlap of DEGs of each RDoC domain, for increasing (left) and decreasing (right) genes, in the aINS.  
601 Overlapping DEGs are indicated by intersecting lines among different domains. (D) Upset plots showing  
602 overlapping DEGs for each RDoC domain, for increasing (left) and decreasing (right) genes, in the dACG.  
603 (E) Heatmap showing overlapping and distinct regulatory pathways for each RDoC domain in aINS and  
604 dACG (F). Colors indicate whether pathways are up- (red) or down-regulated (blue), and color depths  
605 represent significance levels of the enriched pathways.

606


607 **Supplemental Figure Legends**

608

609 **Figure S1. Identification of covariates in GLM differential expression model**

610 (A-D) Principal component analysis of group, brain region, sex, and sequence batch. Colors indicate  
611 sample subgroups under different conditions. (E) Pearson correlation matrix between the first five PCs  
612 from principal component analysis, potential variables of interest, and the first two surrogate variables  
613 from surrogate variable analysis. Colors indicate positive (red) and negative (blue) correlations. Dot size  
614 in the upper-right panel and numbers in the lower-left panel indicate the significant correlation  
615 coefficients.

616



# Figure 2

